BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-507@pharmaconomics
DTSTAMP:20260707T034504Z
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260224
SUMMARY:GOSS Phase 2 — seralutinib
DESCRIPTION:Phase 2 trial results for seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are due Feb 23\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000004/proseratlrwebcastslides-.htm\n\nTrack it: https://www.pharmaconomics.com/e/507
URL:https://www.pharmaconomics.com/e/507
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GOSS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR